The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function

This study has been completed.

Study NCT00973557 Information provided by Cedars-Sinai Medical Center

First Received on September 8, 2009. Last Updated on February 6, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Colorectal Cancer
Lung Cancer
Breast Cancer
Glioblastoma

Additional conditions recognized in this trial

Breast Neoplasms
Colorectal Neoplasms
Lung Neoplasms

Additional drug interventions recognized in this trial

Bevacizumab
Endothelial Growth Factors
Mitogens

More general drug interventions related to this trial

Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

Sponsors listed in this trial

Cedars-Sinai Medical Center

Back to top of Main Content